Get the Stockscreener App
330.27
2.85%
-9.70
After Hours:
330.01
-0.26
-0.08%
Madrigal Pharmaceuticals Inc stock is traded at $330.27, with a volume of 346.48K.
It is down -2.85% in the last 24 hours and up +2.95% over the past month.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
See More
Previous Close:
$339.97
Open:
$340
24h Volume:
346.48K
Relative Volume:
0.75
Market Cap:
$7.20B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-13.15
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
-2.37%
1M Performance:
+2.95%
6M Performance:
+23.90%
1Y Performance:
+63.95%
1-Day Range:
$329.99
$349.28
1-Week Range:
$322.00
$349.28
52-Week Range:
$168.25
$368.29
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
330.27 | 7.20B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Mirae Asset Global Investments Co. Ltd. Sells 6,643 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Rheos Capital Works Inc. Reduces Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
This Stock Just Doubled in 1 Day -- Is It Still a Buy? - The Motley Fool
Madrigal Pharmaceuticals CEO sells shares worth $531,020 - MSN
(01/29/25) Top Picks 2025: Madrigal Pharmaceuticals (MDGL) - Moneyshow.com
Madrigal Pharmaceuticals CEO sells shares worth $531,020 By Investing.com - Investing.com Australia
Madrigal Pharmaceuticals executive sells shares worth $34,529 - MSN
Madrigal Pharmaceuticals chief commercial officer sells $116,328 in stock - MSN
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Insider Carole Huntsman Sells 347 Shares - MarketBeat
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CEO Sells 1,584 Shares of Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Sells 648 Shares of Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Sells 103 Shares of Stock - MarketBeat
Madrigal Pharmaceuticals chief commercial officer sells $116,328 in stock By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals executive sells shares worth $34,529 By Investing.com - Investing.com Canada
(MDGL) Trading Advice - Stock Traders Daily
Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis - MarketBeat
Exploring Three High Growth Tech Stocks in the United States - Yahoo Finance
Brokers Issue Forecasts for MDGL FY2025 Earnings - MarketBeat
Cantor Fitzgerald Estimates MDGL FY2025 Earnings - Defense World
MDGL (Madrigal Pharmaceuticals) Long-Term Debt & Capital Le - GuruFocus.com
Cantor Fitzgerald Predicts MDGL FY2025 Earnings - MarketBeat
MDGL (Madrigal Pharmaceuticals) Dividends per Share : $0.00 (TTM As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals’ Treatment Could Be a Blockbuster in the Making - TipRanks
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales - MSN
MDGL (Madrigal Pharmaceuticals) Change In Working Capital : $7.82 Mil (TTM As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals exec sells $461,789 in stock - MSN
Madrigal Pharmaceuticals gains amid takeover speculation - MSN
MDGL (Madrigal Pharmaceuticals) Quick Ratio : 5.93 (As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH - Seeking Alpha
Have Insiders Sold Madrigal Pharmaceuticals Shares Recently? - Simply Wall St
MDGL (Madrigal Pharmaceuticals) Net Income From Continuing Operations : $-518.67 Mil (TTM As of Sep. 2024) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) EV-to-EBITDA : -10.99 (As of Jan. 19, 2025) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Capex-to-Operating-Cash-Flo - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Earnings Yield % : N/A% (As of Jan. 19, 2025) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) 3-Year Book Growth Rate : 9.60% (As of Sep. 2024) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Debt-to-Asset : 0.11 (As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals executive sells shares worth $120,847 - MSN
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Robert E. Waltermire Sells 442 Shares - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Sells $461,789.49 in Stock - MarketBeat
Madrigal Pharmaceuticals exec sells $461,789 in stock By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals general counsel sells $75,734 in stock By Investing.com - Investing.com Australia
Madrigal Pharmaceuticals general counsel sells $75,734 in stock - Investing.com India
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Up 7.4%Should You Buy? - MarketBeat
Shannon T. Kelley Sells 277 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock - MarketBeat
Madrigal Pharmaceuticals executive sells shares worth $120,847 By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):